High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial

High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial

In contrast to resource-rich countries, most HIV-infected patients in resource-limited countries receive treatment without virological monitoring. There are few long-term data, in this setting, on rates of viral suppression or switch to second-line antiretroviral therapy. The DART trial compared cli...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Kityo, C, Gibb, D, Gilks, C, Goodall, R, Mambule, I, Kaleebu, P, Pillay, D, Kasirye, R, Mugyenyi, P, Walker, A, Dunn, D
Format:	Journal article
Sprache:	English
Veröffentlicht:	Public Library of Science 2014

Ähnliche Einträge

High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
von: Cissy Kityo, et al.
Veröffentlicht: (2014-01-01)

DART and laboratory monitoring of HIV treatment Reply
von: Walker, A, et al.
Veröffentlicht: (2010)

Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).
von: Gilks, C, et al.
Veröffentlicht: (2012)

Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study.
von: Gomo, Z, et al.
Veröffentlicht: (2014)

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
von: Mugyenyi, P, et al.
Veröffentlicht: (2010)

Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
von: Ndembi, N, et al.
Veröffentlicht: (2010)

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.
von: Walker, A, et al.
Veröffentlicht: (2010)

A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria
von: Gilks, C, et al.
Veröffentlicht: (2013)

Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
von: Stöhr, W, et al.
Veröffentlicht: (2011)

Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.
von: Ssali, F, et al.
Veröffentlicht: (2006)

Clinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial
von: Parikh, S, et al.
Veröffentlicht: (2013)

Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe.
von: Muyingo, S, et al.
Veröffentlicht: (2008)

Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.
von: Walker, A, et al.
Veröffentlicht: (2012)

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.
von: Reid, A, et al.
Veröffentlicht: (2008)

The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models.
von: Ford, D, et al.
Veröffentlicht: (2015)

Cost Effectiveness Analysis of Clinically Driven versus Routine Laboratory Monitoring of Antiretroviral Therapy in Uganda and Zimbabwe
von: Lara, A, et al.
Veröffentlicht: (2012)

The impact of different CD4 cell-count monitoring and switching strategies on mortality in HIV-infected African adults on antiretroviral therapy: an application of dynamic marginal structural models
von: Ford, D, et al.
Veröffentlicht: (2015)

The impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe.
von: Kiwuwa-Muyingo, S, et al.
Veröffentlicht: (2012)

Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.
von: Munderi, P, et al.
Veröffentlicht: (2011)

Clinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial.
von: Sujal M Parikh, et al.
Veröffentlicht: (2013-01-01)

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
von: Munderi, P, et al.
Veröffentlicht: (2010)

Lack of minority K65R-resistant viral populations detected after repeated treatment interruptions of tenofovir/zidovudine and lamivudine in a resource-limited setting.
von: McCormick, A, et al.
Veröffentlicht: (2010)

Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
von: Gibb, D, et al.
Veröffentlicht: (2012)

Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
von: Paton, N, et al.
Veröffentlicht: (2014)

CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI Substudy.
von: Serwanga, J, et al.
Veröffentlicht: (2011)

Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa
von: Hakim, J, et al.
Veröffentlicht: (2017)

Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.
von: Antonieta Medina Lara, et al.
Veröffentlicht: (2012-01-01)

Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.
von: Kasirye, P, et al.
Veröffentlicht: (2012)

Monitoring of highly active antiretroviral therapy in HIV infection.
von: Walker, A, et al.
Veröffentlicht: (2011)

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min
von: Ross, LL, et al.
Veröffentlicht: (2019)

Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
von: Gibb, D, et al.
Veröffentlicht: (2002)

Assessment of second-line antiretroviral regimens for HIV therapy in Africa
von: Paton, N, et al.
Veröffentlicht: (2014)

Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection.
von: Gibb, D, et al.
Veröffentlicht: (2004)

Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects
von: Haberer, J, et al.
Veröffentlicht: (2011)

Dynamics of emergence and linkage of HIV reverse transcriptase Q151M MDR complex in children within first-line antiretroviral rollout uncovered by single-genome sequencing
von: Mbisa, J, et al.
Veröffentlicht: (2009)

CD8+ T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4+ T Cells <200 Cell/μL: The DART Trial STI Substudy
von: Jennifer Serwanga, et al.
Veröffentlicht: (2011-01-01)

Professor Raymond Dart
von: J. D. Verster
Veröffentlicht: (1961-06-01)

Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.
von: Bwakura-Dangarembizi, M, et al.
Veröffentlicht: (2015)

Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy
von: Stöhr, W, et al.
Veröffentlicht: (2013)

Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
von: Kityo, C, et al.
Veröffentlicht: (2010)